Atrial Fibrillation.

Slides:

Advertisements

Similar presentations

Improving Stroke Prevention in Patients With Atrial Fibrillation.

Advertisements

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Identifying patients with atrial fibrillation and "truly low" thromboembolic risk who are poorly characterized by CHA2DS2-VASc: Superior performance of.

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Anticoagulation in Atrial Fibrillation

Covering the Bases in Cardioversion

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Atrial Fibrillation and PCI

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

The ABCs of AF.

Access to NOAC Therapy:

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Nat. Rev. Cardiol. doi: /nrcardio

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Relative Risk of Events by CHA2DS2-VASc Score

Dos and Don’ts for High-Risk Elderly Patients With AF

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Aspirin and Cardioprevention in 2018

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

CAD/PAD in Primary Care

What You Didn't Know About AF and Renal Dysfunction

A Case Challenge.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

NOAC Studies in VTE AF Studies Superior Outcomes.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in patients with atrial fibrillation: the Swedish Atrial Fibrillation.

Factor Xa Inhibitors in Coronary Artery Disease

The ABCs of AF.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

NOACs and Reversal Agents

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Reassessing Risk Stratification in CAD/PAD

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Atrial Fibrillation

Long-Term Outcomes in Patients With AF

ICH in Asians

Causes of Death in Patients With AF 2-Year Outcome Data From GARFIELD-AF

Assessing Risk CHA2DS2-VASc

Event Rates Stratified by CHA2DS2-VASc

Meta-Analysis of NOACs vs Warfarin

Factors by Which Bleeding Affects Short- and Long-Term CV Outcomes

Assessing Bleeding Risk HAS-BLED

Risk Factors in Patient With AF Heterogeneous or Homogeneous?

Role of Ethnicity and Lifestyle in Assessing Risk of CHD

ESC Guidelines Stroke Prevention in AF

Recommendations for Stroke Prevention in Patients With AF

AF and Comorbidities Insights From ENGAGE AF-TIMI 48

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)